Background Millions of peripheral intravenous catheters are used worldwide. The current guidelines recommend routine catheter replacement every 72-96 h. This practice requires increasing healthcare resource use. The clinically indicated catheter replacement strategy is proposed as an alternative. Objectives To assess the cost effectiveness of clinically indicated versus routine replacement of peripheral intravenous catheters. Methods A cost-effectiveness analysis from the perspective of Queensland Health, Australia, was conducted alongside a randomized controlled trial. Adult patients with an intravenous catheter of expected use for longer than 4 days were randomly assigned to receive either clinically indicated replacement or third-day routine replacement. The primary outcome was phlebitis during catheterization or within 48 h after catheter removal. Resource use data were prospectively collected and valued (2010 prices). The incremental net monetary benefit was calculated with uncertainty characterized using bootstrap simulations. Additionally, value of information (VOI) and value of implementation analyses were performed. Results The clinically indicated replacement strategy was associated with a cost saving per patient of AU$7.60 (95 % confidence interval [CI] 4.96-10.62) and a non-significant difference in the phlebitis rate of 0.41 % (95 % CI -1.33 to 2.15). The incremental net monetary benefit was AU$7.60 (95 % CI 4.96-10.62). The expected VOI was zero, whereas the expected value of perfect implementation of the clinically indicated replacement strategy was approximately AU$5 million over 5 years. Conclusion The clinically indicated catheter replacement strategy is cost saving compared with routine replacement. It is recommended that healthcare organizations consider changing to a policy whereby catheters are changed only if clinically indicated.
Introduction
Peripheral venous catheters are commonly used to deliver medications, fluids, blood products and nutritional supplements intravenously. Up to 70 % of patients in acute care hospitals need a short peripheral intravenous catheter; about 330 million are sold each year in the USA alone [1] . Insertion of intravenous catheters is an invasive procedure, which can cause discomfort for patients and is associated with complications such as irritation of the vein (phlebitis) in 2.3-60 % and catheter-related bloodstream infections (CRBSI) in 0.1 % of cases [2] [3] [4] . To reduce the incidence of these adverse events in adult patients, the current guidelines from the US Centers for Disease Control and Prevention (CDC) recommend routine intravenous catheter replacement no more frequently than every 72-96 h [5] . This routine replacement is the current practice in most hospitals around the world, although it subjects patients to repeated invasive procedures and increases healthcare costs. [6, 7] Interestingly, recent studies have found no evidence to support routine replacement of catheters as a measure to mitigate catheter-related complications [6, [8] [9] [10] . A recently published trial by Rickard and colleagues [7] tested whether patients who had their peripheral intravenous catheters replaced when clinically indicated would have equivalent rates of phlebitis and other complications but reduced healthcare resource use and costs compared with patients who had routine catheter replacement every 3 days. Patients in the clinically indicated group had their intravenous catheters removed only for completion of therapy, phlebitis, infiltration, occlusion, accidental removal or suspected infection [7] . The aim of this study was to compare the cost effectiveness of the two approaches of clinically indicated versus routine replacement of peripheral venous catheters on the basis of the results of the clinical trial of Rickard et al. [7] , within the context of the public health system in Queensland, Australia. In addition, value of information (VOI) and value of implementation analyses were undertaken to characterize decision uncertainty and to inform if the implementation of the recommended strategy is worthwhile.
Methods

Clinical Trial Design and Results
Full details of the design and results of the clinical trial have been reported elsewhere [7] . Briefly, this was a multicentre, randomized, non-blinded equivalence trial, which recruited adult patients with an intravenous catheter of expected use for longer than 4 days from three hospitals in Queensland, Australia, between 2008 and 2009. Computer-generated random assignment was to clinically indicated replacement or third-day routine replacement. Patients in the clinically indicated group had their intravenous catheters removed only for completion of therapy, phlebitis, infiltration, occlusion, accidental removal or suspected infection [7] . The primary outcome was phlebitis during catheterization or within 48 h after removal. The primary analysis was by intention to treat. Of the 3,379 eligible patients, 3,283 were enrolled, and they were all included in the analysis (1,593 clinically indicated; 1,690 routine replacement). The patients' characteristics were comparable across the two groups. Phlebitis occurred in 114 of 1,690 patients (6.75 %) in the routine replacement group and in 114 of 1,593 patients (7.16 %) in the clinically indicated group, an absolute risk difference of 0.41 % (95 % confidence interval [CI] -1.33 to 2.15 %) [7] . Catheter-related bloodstream infections were rare in both groups at 1 per 3,283 patients (0.03 %); no serious adverse events related to the study interventions occurred (Table 1) .
Resource Use Measurement
Healthcare resource utilization data were collected alongside the clinical trial for the two study groups. These resources included equipment required for insertion and removal of intravenous catheters, and staff time to insert and remove the catheters ( Table 2 ). The equipment required for each intervention arm was valued using negotiated hospital supply contract rates (2010) from the perspective of the state health department, Queensland Health, Australia. On the basis of the observed rates of 14.5 min per insertion and 4.5 min per removal, the staff time was valued at the fixed industrial award wage rates in Australia (2010) [7] .
Analysis
Cost-Effectiveness Analysis
The economic evaluation was from the perspective of Queensland Health. The net monetary benefit (NB) approach was used for the cost-effectiveness analysis [11] . The NB for each strategy was calculated by multiplying its effect outcome by the willingness-to-pay (WTP) threshold and subtracting cost. The strategy with the maximum mean NB would be the preferred option. The incremental net monetary benefit (INB) is the difference between the NBs of the compared strategies, and it represents the net gain from the introduction of the new strategy. Because the primary outcome of the trial was the phlebitis rate, which is an adverse event, the effect outcome chosen for the costeffectiveness analysis was the rate of phlebitis avoided (i.e. 1 -phlebitis rate). A WTP threshold was set at AU$0.00 per phlebitis case avoided, since treatment of phlebitis typically consisted only of removal and replacement of the affected intravenous catheter, which was already accounted for in the cost calculations. The 95 % non-parametric CI (percentile method) based on 1,000 bootstrap replications was calculated to characterize the uncertainty in the INB [12] . A cost-effectiveness acceptability curve (CEAC) was plotted to show the probability of one of the two strategies being cost effective across a range of possible WTP thresholds [13] .
The clinical trial directly compared the two alternative strategies of catheter replacement and prospectively captured all relevant outcomes and costs; therefore, an economic evaluation based on the trial data alone was considered sufficient (i.e. there was no need for modelling). Because the time horizon of the analysis was 1 month, the total costs and effect outcomes were not discounted.
Value of Information Analysis
VOI analysis is a systematic approach to measure uncertainty surrounding the results of cost-effectiveness analyses [14] . The analysis would usually start by calculating the expected value of perfect information (EVPI). The EVPI is the difference between the net benefit of a decision given perfect information and the net benefit of the decision based on current information [14] . The population EVPI would be estimated by multiplying the calculated EVPI by the number of patients expected to benefit from this intervention over a given time horizon. The population that would benefit from the cost-effective strategy in Queensland public hospitals over the coming 5 years (discounted at 5 %) was estimated to be approximately 680,000. This is based on the assumption that one third of the 450,000 overnight admissions per year (150,000) would need catheter placement for more than 3 days [15] . The population EVPI reflects the magnitude of uncertainty in the results of a cost-effectiveness analysis and represents the maximum (upper bound) value for conducting further research to resolve this uncertainty [14] . If further research appears potentially worthwhile on the basis of the Table 1 Trial outcomes per group based on intention-to-treat analysis [7] Clinically indicated replacement (n = 1,593) AS administration set, AU$ Australian dollars population EVPI, the value of resolving uncertainty surrounding a particular parameter (e.g. cost, effect) would be estimated by calculating the expected value of perfect parameter information (EVPPI) [14] . To inform the value of a proposed future trial design (e.g. sample size) that could reduce uncertainty surrounding our results, the expected value of sample information (EVSI) would be calculated [16, 17] . If the EVPI was small (approaching zero), then there would be very little uncertainty surrounding the findings of our cost-effectiveness analysis, and there would be no need to estimate the EVPPI or the EVSI. Our focus in this case should be directed to the implementation of the strategy that was expected to be cost effective [18] . Methods to calculate the above VOI measures are described in detail elsewhere [19] [20] [21] . In general, VOI analysis was performed using Monte Carlo simulation. Random values for the estimated NBs were sampled repeatedly (10,000 iterations) from the normal distribution of the mean NB of each intervention, based on the central limit theorem [19] . Then, the NB for each strategy at each iteration was calculated to identify the optimal strategy. Averaging the maximum NBs from all iterations and subtracting from this the mean NB of the preferred strategy (calculated from the cost-effectiveness analysis) would give the EVPI. Assuming that the NB was a linear function of the cost and effect parameters, the same one-level Monte Carlo simulation technique would be used to calculate the EVPPI for the parameters of interest [19] . Similarly, the EVSI for a proposed trial of a given sample size could be calculated by sampling from the updated distribution (using Bayesian updating) of the mean NB for each strategy [21] .
Value of Implementation Analysis
The expected value of perfect implementation (EVPIm) is the difference between the expected benefit of perfectly implementing the cost-effective strategy and the expected benefit of this strategy with suboptimal implementation [18] :
P is the proportion of the eligible population that is currently benefiting from the preferred strategy, which can take values between 0 and 1. The population EVPIm was calculated by multiplying the EVPIm from the above equation by the number of Queensland Health patients who would benefit from the preferred strategy over the coming 5 years (i.e. 680,000). The population EVPIm could inform the cost effectiveness of programmes to improve the implementation of the preferred strategy. 
Results
Resource Use
Cost
Cost results are reported in Table 4 . The routine replacement group incurred an equipment cost of AU$47.80 (SD $30.00) and a staff cost of AU$21.50 (SD $14.10). For the clinically indicated replacement group, the average costs for the equipment and staff were AU$42.50 (SD $27.00) and AU$19.20 (SD $13.10), respectively. The clinically indicated replacement group had a lower total cost (AU$61.70, SD $39.50 versus AU$69.30, SD $43.50), with a statistically significant reduction in the total cost of AU$7.60 (95 % CI 4.96-10.62) per patient.
Cost Effectiveness
At a WTP of AU$0.00, the clinically indicated catheter replacement strategy was associated with a higher NB than the routine-replacement strategy (-AU$61.70 versus -AU$69.30), indicating that clinically indicated replacement is the preferred strategy ( Table 5 ). The INB was AU$7.60 (95 % CI 4.96-10.62) in cost saving. Figure 1 presents the INB in Australian dollars with the 95 % uncertainty interval across a range of values for the WTP. From the CEAC, the probability of the clinically indicated replacement strategy being cost effective was greater than 95 % as long as the WTP threshold was less than AU$350 per phlebitis case avoided (Fig. 2) .
Value of Information Analysis
The VOI analysis estimated the EVPI to be AU$0.00 per patient for the proposed WTP threshold of AU$0.00. Because the EVPI is the upper bound for the cost of uncertainty, the EVSI would be also AU$0.00. The EVPI was found to remain around AU$0.00 as long as the WTP threshold per phlebitis case avoided was below AU$350 (Fig. 2) .
Value of Implementation Analysis
Assuming that the current implementation of the clinically indicated catheter replacement is zero, the value of perfectly implementing this strategy (EVPIm) on the basis of the results of the cost-effectiveness analysis would be the NB of the clinically indicated replacement strategy. The population EVPIm was estimated to be around AU$5 million (680,000 9 AU$7.60) for Queensland public hospitals over the coming 5 years.
Discussion
This study presents a cost-effectiveness analysis and VOI, based on a multicentre randomized controlled trial comparing clinically indicated versus routine replacement of intravenous peripheral venous catheters. The clinical analysis concluded that the two strategies had the same rates of phlebitis and other complications, including bloodstream infections. The cost-effectiveness analysis showed that the clinically indicated replacement strategy was associated with a significant reduction in healthcare resource use in terms of equipment and staff time, resulting in an average cost reduction of AU$7.60 per patient. Because patientlevel data on cost and effect were available from the clinical trial, the decision was made to conduct a full costeffectiveness analysis to estimate the joint density of cost and effect differences and present uncertainty on a costeffectiveness acceptability curve. Performing a cost-minimization analysis based on the equivalence in effect could result in biased estimation of uncertainty surrounding the results [22] . A VOI analysis was also undertaken to measure this uncertainty and to assess whether the evidence from the clinical trial is sufficient to change current practice.
The results of the cost-effectiveness analysis suggested that adopting the clinically indicated catheter replacement strategy would result in an INB of AU$7.60 per patient; the probability of this strategy being cost effective approached AU$ Australian dollars, CI confidence interval, NB net benefit, SD standard deviation a Willingness-to-pay threshold = AU$0.00 Fig. 2 Cost-effectiveness acceptability curve (CEAC) and the expected value of perfect information (EVPI) Fig. 1 The incremental net benefit (INB) of the clinically indicated replacement strategy with 95 % uncertainty boundaries (from 1,000 bootstraps) 100 % as long as the WTP per phlebitis case avoided was below AU$350. The EVPI was also approaching zero under this WTP threshold, suggesting negligible uncertainty and minimal value of additional research. This is one example of how the VOI analysis can support new strategies when decisions on strategy adoption and the need for further research are taken simultaneously. Because, globally, a large number of patients need intravenous catheters, there is significant value in implementing the findings of this study by changing current guidelines to recommend catheter replacement only if clinically indicated. The EVPIm in Queensland public hospitals over the coming 5 years was approximately AU$5 million. This benefit of implementation would amount to higher figures if this strategy was implemented worldwide. For example, of the 37 million patients admitted to hospitals each year in the USA alone [23] , if one third (12.5 million) needed a catheter for more than 3 days, then a change to clinically required replacement would prevent around 2.5 million unnecessary intravenous catheter insertions and would save up to 1 million hours of staff time. The expected monetary value of perfectly implementing this strategy in the USA alone over 5 years would be around US$400 million in health cost savings. To implement this strategy, hospitals with a routine catheter replacement practice already in place would need to change current policies and develop protocols to allow regular patient assessment and subsequent catheter removal or replacement for phlebitis or other complications, or when therapy has been completed. Nevertheless, the expected cost of implementation is less likely to exceed the benefits from adopting the proposed strategy.
This study had a number of limitations. First, the analysis was based on a single clinical trial from Australia. However, the clinical trial was multisite with a large sample size (3,283 patients), with high-quality methods to eliminate selection, allocation and detection bias, together with 100 % follow-up for the primary endpoint. Furthermore, the results of this study are in line with the findings from previous smaller randomized trials and a recent systematic review [6, 8, 10] . Second, the resources that were measured included equipment and staff time but excluded other resources such as the hospital stay. Nevertheless, patients in the two groups were well matched in their baseline characteristics, including the reasons for admission, and it is unlikely that the hospital stay would be prolonged because of the complications associated with the compared strategies (e.g. phlebitis). Third, measuring and valuing different resources were from the perspective of one health department, Queensland Health. However, different jurisdictions and organizations can assign local values to relevant resources in order to have more accurate estimates of the magnitude of cost savings. We would expect that the relative costs of the key resources valued in these analyses (e.g. nursing time, catheter equipment) would be similar in other jurisdictions. The other assumption that was made was the WTP threshold of AU$0.00; however, the effect of varying WTP values on the findings of the cost-effectiveness analysis is clearly presented in the 'Results' section. Finally, because of the acute nature of this intervention, it was difficult to measure the effect of each strategy on the quality of life of the hospitalized patients and to conduct a cost utility analysis. Patients are presumably unlikely to want routine catheter replacement, since insertion of an intravenous catheter is painful, requiring piercing of the skin, tissue and vein with a steel needle at least once-or several times for a difficult insertion [7] .
Conclusion
There was no significant difference in the rate of phlebitis or other complications between the clinically indicated and routine peripheral catheter replacement strategies. Changing catheters only when clinically indicated reduces healthcare resource use and saves costs. Healthcare organizations should consider changing current policies to recommend clinically indicated replacement of peripheral intravenous catheters.
